Abbisko Therapeutics

Abbisko Therapeutics Reports Positive Phase 2 Lavengratinib Data

Shanghai, China, September 21, 2026 Abbisko Therapeutics has announced positive preliminary results from a Phase 2 clinical study evaluating...

By cGxPwire Editor
September 23, 2026

Bio-Pharma

Abbisko and AstraZeneca Advance Oral PD-L1 Therapy for NSCLC

SHANGHAI, China, July 1, 2026 Abbisko Therapeutics and AstraZeneca have entered into a strategic collaboration to advance the clinical...

By cGxPwire Editor
July 3, 2026

M&A

Abbisko Therapeutics and Lilly Expand Global R&D Partnership

SHANGHAI, June 23, 2026 Abbisko Therapeutics Co., Ltd. announced a strategic research collaboration and license agreement with Eli Lilly...

By cGxPwire Editor
June 24, 2026

Pharma

Abbisko Pimicotinib NDA Progress Advances TGCT Therapy

Shanghai, China – April 22, 2026 In a major milestone for rare tumor therapeutics, Abbisko Therapeutics has announced significant...

By cGxPwire Editor
April 23, 2026

Pharma

Abbisko Irpagratinib Gains EMA Orphan Drug Status

SHANGHAI, China, March 31, 2026 Abbisko Therapeutics has announced that its investigational FGFR4 inhibitor irpagratinib (ABSK-011) has been granted...

By cGxPwire Editor
April 1, 2026

We work Hard to get you posted with latest updates

Unwrap our new Directory